PRMT5-mediated FUBP1 methylation accelerates prostate cancer progression

Weiwei Yan, Yang Liu, Xuefeng Qiu, Xuebin Zhang, Jiahui Chen, Kai Xiao, Ping Wu, Chao Peng, Xiao Hu, Zengming Wang, Jun Qin, Li-Ming Sun, Luonan Chen, Denglong Wu, Shengsong Huang, Lichen Yin, Zhenfei LiJournal of Clinical Investigation 2024 · DOI

TL;DR

This study identifies a novel mechanism driving prostate cancer progression: the methylation of the FUBP1 protein by PRMT5. Targeting this methylation with a specially designed peptide delivered via nanocomplexes effectively suppressed tumor growth in preclinical models, offering a promising new therapeutic avenue beyond traditional hormone therapies.

What Problem Does This Paper Address?

Prostate cancer remains a significant health challenge, and while hormone therapies are effective initially, patients often develop resistance. This necessitates the development of novel therapeutic strategies. This paper addresses the need for new targets by investigating the role of the transcription factor FUBP1 and its post-translational modifications in prostate cancer progression, aiming to uncover mechanisms that drive the disease and identify potential therapeutic interventions.

Methods

The researchers employed a multi-pronged approach:

  • In vitro studies: They used various prostate cancer cell lines (LNCaP, C4-2, VCaP, Du145, 22Rv1, LAPC4, PC3) and HEK293T cells to investigate FUBP1's function and its interaction with PRMT5. Techniques included:
  • Gene knockdown/knockout: Using shRNA and CRISPR/Cas9 to reduce FUBP1 and PRMT5 levels.
  • Protein analysis: Western blotting to assess protein expression and methylation status (using a newly developed meFUBP1 antibody).
  • Immunoprecipitation (IP): To study protein-protein interactions between FUBP1 and PRMT5.
  • In vitro methylation assays: To confirm PRMT5's ability to methylate FUBP1.
  • Cell proliferation assays: To measure the impact of FUBP1 and its methylation on cancer cell growth.
  • Transcriptomic analysis (RNA-Seq): To understand the global gene expression changes upon FUBP1 knockdown.
  • In vivo studies:
    • Xenograft models: Implanting human prostate cancer cells into immunocompromised mice to assess the effect of FUBP1 manipulation on tumor growth.
  • Genetic mouse models: Developing and utilizing genetically engineered mice (TRAMP and Pten-deficient models) with specific FUBP1 mutations to study the role of FUBP1 methylation in a more physiological context.
  • Therapeutic development:
    • Peptide design: Synthesizing a competitive peptide (PUBLISH) based on the FUBP1-PRMT5 interaction domain.
  • Nanocomplex delivery: Encapsulating the peptide within branched poly(β-amino ester) (BPAE) and hyaluronic acid (HA)-decorated nanocomplexes for efficient intracellular delivery.
  • Clinical relevance:
    • Tissue microarray (TMA) analysis: Immunohistochemistry (IHC) on patient samples to correlate PRMT5, FUBP1, and meFUBP1 levels with tumor characteristics and patient outcomes (biochemical recurrence).

Datasets

  • The Cancer Genome Atlas (TCGA): Used for correlation analysis of FUBP1 expression with biochemical recurrence in prostate cancer patients.
  • Chinese Prostate Cancer Genome and Epigenome Atlas: Used for similar correlation analyses.
  • Human Prostate Cancer Tissue Microarray: A custom-built array of 107 paired tumor and adjacent non-cancerous tissue samples from prostatectomy patients, used for IHC analysis.
  • RNA-Seq data: Generated from LNCaP and C4-2 cells with FUBP1 knockdown, deposited in the National Omics Data Encyclopedia (NODE) under accession number OEP004234.

Key Insights and Ideas

  • FUBP1 is a key driver of prostate cancer progression: Beyond its known roles in transcription and RNA processing, FUBP1's oncogenic function in prostate cancer is significant, impacting cell proliferation and tumor growth.
  • FUBP1 methylation is critical for its oncogenic activity: The study reveals that PRMT5-mediated methylation of FUBP1 at specific arginine residues (R359/R361/R363) is essential for its pro-tumorigenic effects. A mutant FUBP1 lacking these methylation sites fails to promote cancer progression.
  • BRD4 acts upstream of PRMT5: The bromodomain protein BRD4 plays a crucial role by transcriptionally regulating PRMT5 and MTAP, thereby influencing FUBP1 methylation. This highlights a novel regulatory axis.
  • Targeting FUBP1 methylation is a viable therapeutic strategy: A competitive peptide designed to block FUBP1-PRMT5 interaction, delivered via nanocomplexes, effectively inhibited FUBP1 methylation and suppressed prostate cancer growth in preclinical models. This offers a more specific approach than directly inhibiting PRMT5.
  • meFUBP1 as a potential biomarker: The presence and level of methylated FUBP1 (meFUBP1) correlate with PRMT5 levels and are associated with earlier biochemical recurrence, suggesting its potential as a biomarker for disease progression and treatment response.

Key Results

  • FUBP1 knockdown significantly impedes prostate cancer cell proliferation and xenograft growth.
  • PRMT5 directly methylates FUBP1 at R359/R361/R363.
  • FUBP1 mutants lacking these methylation sites are unable to rescue FUBP1 knockdown-induced suppression of cell growth and tumor formation.
  • BRD4 inhibition leads to decreased PRMT5 and MTAP expression, subsequently reducing FUBP1 methylation.
  • Increased levels of PRMT5, FUBP1, and meFUBP1 are observed in tumor tissues compared to adjacent normal tissues.
  • High levels of PRMT5, FUBP1, and meFUBP1 correlate with earlier biochemical recurrence in patients.
  • A competitive peptide (PUBLISH) effectively blocks FUBP1-PRMT5 interaction, inhibits FUBP1 methylation, and suppresses prostate cancer cell proliferation and xenograft growth.
  • Nanocomplex delivery of the PUBLISH peptide significantly reduces tumor volume and weight in xenograft models.

Limitations and Future Work

  • Context-specific regulation of FUBP1: The paper notes that while FUBP1's role in prostate cancer is clear, its regulation and function can be context-specific, and further investigation into its mechanisms in other cancer types is warranted.
  • Potential for off-target effects of PRMT5 inhibitors: While the competitive peptide offers improved specificity, the broader implications of PRMT5 inhibition on other substrates in normal cells require careful consideration.
  • Delivery system optimization for different cancers: The authors suggest that the nanocomplex delivery system may need to be tailored for different tumor types and administration routes, particularly for cancers with dense extracellular matrices or requiring specific delivery methods (e.g., bladder infusion).
  • Clinical translation: While promising preclinical results are shown, further studies are needed to evaluate the efficacy and safety of the PUBLISH peptide and its delivery system in human clinical trials.
  • AR signaling independence: The PUBLISH peptide's mechanism is independent of androgen receptor (AR) signaling, suggesting it could be used in combination with hormone therapy for enhanced efficacy. This combination therapy approach warrants further investigation.

Summary updated

Abstract

Strategies beyond hormone-related therapy need to be developed to improve prostate cancer mortality. Here, we show that FUBP1 and its methylation were essential for prostate cancer progression, and a competitive peptide interfering with FUBP1 methylation suppressed the development of prostate cancer. FUBP1 accelerated prostate cancer development in various preclinical models. PRMT5-mediated FUBP1 methylation, regulated by BRD4, was crucial for its oncogenic effect and correlated with earlier biochemical recurrence in our patient cohort. Suppressed prostate cancer progression was observed in various genetic mouse models expressing the FUBP1 mutant deficient in PRMT5-mediated methylation. A competitive peptide, which was delivered through nanocomplexes, disrupted the interaction of FUBP1 with PRMT5, blocked FUBP1 methylation, and inhibited prostate cancer development in various preclinical models. Overall, our findings suggest that targeting FUBP1 methylation provides a potential therapeutic strategy for prostate cancer management.
BibTeX
@article{yan2024prmt,
  author = {Weiwei Yan and Yang Liu and Xuefeng Qiu and Xuebin Zhang and Jiahui Chen and Kai Xiao and Ping Wu and Chao Peng and Xiao Hu and Zengming Wang and Jun Qin and Li-Ming Sun and Luonan Chen and Denglong Wu and Shengsong Huang and Lichen Yin and Zhenfei Li},
  title = {{PRMT5-mediated FUBP1 methylation accelerates prostate cancer progression}},
  journal = {Journal of Clinical Investigation},
  year = {2024},
  doi = {10.1172/jci175023},
}
Figure